Rasmussen N S, Nielsen C T, Houen G, Jacobsen S
Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen Denmark
Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen Denmark.
Lupus. 2016 Dec;25(14):1567-1576. doi: 10.1177/0961203316644334. Epub 2016 Apr 15.
We investigated if signs of active Epstein-Barr virus and cytomegalovirus infections associate with certain autoantibodies and a marker of type I interferon activity in patients with systemic lupus erythematosus. IgM and IgG plasma levels against Epstein-Barr virus early antigen diffuse and cytomegalovirus pp52 were applied as humoral markers of ongoing/recently active Epstein-Barr virus and cytomegalovirus infections, respectively. Plasma galectin-3 binding protein served as a surrogate marker of type I interferon activity. The measurements were conducted in 57 systemic lupus erythematosus patients and 29 healthy controls using ELISAs. Regression analyses and univariate comparisons were performed for associative evaluation between virus serology, plasma galectin-3 binding protein and autoantibodies, along with other clinical and demographic parameters. Plasma galectin-3 binding protein concentrations were significantly higher in systemic lupus erythematosus patients (P = 0.009) and associated positively with Epstein-Barr virus early antigen diffuse-directed antibodies and the presence of autoantibodies against extractable nuclear antigens in adjusted linear regressions (B = 2.02 and 2.02, P = 0.02 and P = 0.002, respectively). Furthermore, systemic lupus erythematosus patients with anti-extractable nuclear antigens had significantly higher antibody levels against Epstein-Barr virus early antigen diffuse (P = 0.02). Our study supports a link between active Epstein-Barr virus infections, positivity for anti-extractable nuclear antigens and increased plasma galectin-3 binding protein concentrations/type I interferon activity in systemic lupus erythematosus patients.
我们研究了活动性爱泼斯坦-巴尔病毒（EB病毒）和巨细胞病毒感染的迹象是否与系统性红斑狼疮患者的某些自身抗体及I型干扰素活性标志物相关。针对EB病毒早期抗原弥散体和巨细胞病毒pp52的IgM和IgG血浆水平，分别作为正在进行/近期活动性EB病毒和巨细胞病毒感染的体液标志物。血浆半乳糖凝集素-3结合蛋白作为I型干扰素活性的替代标志物。使用酶联免疫吸附测定法（ELISA）对57例系统性红斑狼疮患者和29名健康对照者进行了检测。对病毒血清学、血浆半乳糖凝集素-3结合蛋白和自身抗体之间以及与其他临床和人口统计学参数进行了回归分析和单变量比较，以进行关联性评估。系统性红斑狼疮患者的血浆半乳糖凝集素-3结合蛋白浓度显著更高（P = 0.009），并且在调整后的线性回归中与EB病毒早期抗原弥散体定向抗体以及针对可提取核抗原的自身抗体的存在呈正相关（B分别为2.02和2.02，P分别为0.02和0.002）。此外，具有抗可提取核抗原的系统性红斑狼疮患者针对EB病毒早期抗原弥散体的抗体水平显著更高（P = 0.02）。我们的研究支持在系统性红斑狼疮患者中，活动性EB病毒感染、抗可提取核抗原阳性与血浆半乳糖凝集素-3结合蛋白浓度升高/I型干扰素活性增加之间存在联系。
